Articles tagged with Target Proteins
A study by the University of Illinois at Urbana-Champaign found that an individualized diet program can help people lose extra pounds and keep them off. The program uses easy-to-use tools to empower dieters to make informed choices about their food intake.
The SARS-Arena program identifies conserved peptides in the SARS-CoV-2 virus that could be used to develop vaccines. The peptides are part of the nucleocapsid protein, which is highly expressed upon infection and highly immunogenic.
YAP1 controls angiogenesis by expressing genes involved in blood vessel formation, and its activity is regulated by PHD2 and VHL under normal oxygen conditions. In hypoxic conditions, YAP1's nuclear localization enables it to interact with HIF1α, leading to increased expression of pro-angiogenic proteins.
Researchers at Kobe University have successfully identified and disrupted genes in Pichia pastoris yeast to increase its secretory production of useful proteins. Through a series of processes, they developed new host strains that can produce high yields of proteins for industrial enzymes and biomedical antibodies.
Liu's three-year grant will pursue protein-derived cofactor studies to improve understanding of amino acids and their role in metabolism. The research aims to gain a quicker and more thorough understanding of amino acid function and purpose.
Researchers at Texas A&M University are developing mathematical models to predict and control cellular differentiation. They created a technique using mix-and-read assays, which allow for the detection of key signaling proteins in live tissues. This method enables researchers to gain a deeper understanding of how cells make decisions.
Researchers found a protein in eye fluid linked to disease progression in patients with wet age-related macular degeneration. Measuring its levels can accurately predict treatment needs, allowing for safe reduction or cessation of therapies.
Researchers used chemoproteomics to profile 53 HDAC drugs and found many had additional targets beyond their intended HDACs. The study identified MBLAC2 as a common off-target protein that affects extracellular vesicle accumulation.
Researchers report that apratoxin S4, an anticancer drug candidate, can interfere with viral replication in human cells. The compound was effective against multiple viruses, including SARS-CoV-2, influenza A, and Zika virus. Further studies are needed to confirm its potential as a broadly acting antiviral.
The study reveals how the protein binds to ligands and inhibitory antibodies, providing insights into its molecular function. The findings may lead to better targeted therapeutic approaches in the future.
Rensselaer researchers will use a five-year grant to develop novel inhibitors of the SARS-CoV-2 virus's CLpro and PLpro proteases. The team aims to create an orally bioavailable drug that can be administered at home, with the potential for improved antiviral activity when combined with other drugs like remdesivir.
Researchers at the University of New Hampshire have found that a repurposed drug compound can inhibit the activity of SARS-CoV-2's main protease enzyme. This breakthrough could lead to new treatments and slow the spread of COVID-19, an RNA virus known for causing seasonal epidemics.
Researchers discovered that the TCF-1 protein enables plasticity in cells across neighborhoods during T cell development, weakening insulation and increasing interactions between adjacent neighborhoods. This finding sheds new light on immunotherapy approaches and could lead to more efficient cancer treatments.
Scientists have discovered a new, high-resolution view of the rabies virus glycoprotein, which could lead to more effective vaccines. The study's findings suggest that a better-shaped vaccine could provide lifelong protection against the deadly disease.
A novel study has identified metabolic defects, impaired protein secretion, and altered phosphoproteomic signatures in alcohol-associated cirrhosis and hepatitis. These findings may lead to the development of new diagnostic and therapeutic approaches for a disease with limited treatment options.
Scientists at Karolinska Institutet and Stockholm University have visualized the machinery that mitochondria use to form their proteins. This discovery presents opportunities to design more specific antibiotics and cancer drugs.
A new study by the University of Colorado Anschutz Medical Campus explores the effects of multiple mutations in SARS-CoV-2 variants. The findings suggest that certain mutations work together to improve virus fitness, making it challenging for antibody treatments to neutralize new variants.
Researchers at Karolinska Institutet found a link between genetic variants in diabetes drug targets and lower Alzheimer's disease risk. The study suggests that the target protein, KATP channel, may be a therapeutic target for treating and preventing Alzheimer's disease.
Researchers have developed a new tool to visualize leukocytes in the brain vasculature during in vivo two-photon laser scanning microscopy. The tool uses a fluorescent antibody targeting CD45, a ubiquitously expressed protein on white blood cells, allowing for tracking of circulating leukocytes over time and space.
A recent study published in Nature Communications has significantly extended the understanding of one type of protein degrader technology, expanding on current validation strategies. This breakthrough could boost the number of drugs successfully entering human trials, particularly for hard-to-treat cancers.
Researchers at Gwangju Institute of Science and Technology have developed a new bioinformatics pipeline, CRESSP, to investigate the mechanism underlying autoimmune diseases following SARS-CoV-2 infection. The tool identified potential epitopes responsible for COVID-related autoimmune diseases and predicted cross-reactive epitopes of di...
Researchers at Johns Hopkins Medicine have designed nanobodies derived from llama antibodies to target specific sodium ion channels in human muscle cells. This breakthrough could lead to safer and more efficient treatments for pain during surgery and irregular heart rhythms, as well as seizure control.
Researchers at Ochsner Health and MD Anderson have discovered that blocking interleukin-6 (IL-6) in lab models improves cancer responses while minimizing inflammation in healthy tissue. By targeting this cytokine, immune checkpoint inhibitors may become more targeted on tumors with fewer side effects.
Researchers at the University of Missouri are applying AI to analyze protein dynamics, identifying potential target sites for new drug therapies. The approach can simulate protein changes related to conditions like cancer, enhancing the chances of successful therapies.
Researchers have identified potential biomarkers in lupus nephritis through large-scale protein analysis, which may replace invasive tests. The study's findings could lead to more accurate diagnosis and treatment of the disease.
Researchers at DTU Compute and DIKU have developed a machine learning model that can map the potential of proteins, enabling the biotech industry to accelerate the development of new proteins. The model generates a picture of how proteins are linked, allowing for the identification of closely related proteins with desirable properties.
A new lab test has been developed by Rutgers scientists to identify COVID-19 variants. The test uses molecular beacon technology and can detect eight different mutations in the spike protein, increasing the transmissibility of the virus and evading immune defenses.
A new Cambridge study has discovered that the sex of a fetus can affect placenta function, diet-induced maternal obesity, and stress. Designing sex-specific therapies and personalized lifestyle interventions could have lifelong health benefits for children.
The new computational tool, AF2Complex, predicts the structure of protein complexes and their interactions, offering insights into biomolecular mechanisms. The model is based on AlphaFold 2 and performs well in predicting protein structures and complex formations.
Researchers developed a bioinformatics platform called REFLECT to predict optimal combination therapies based on co-occurring tumor alterations. The tool selected combinations that resulted in improved patient outcomes across pre-clinical and clinical studies, leading to increased durable responses.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Scientists are working on understanding the interplay between flaviviruses and mitochondria in hopes of finding new treatment options. By deciphering this process, researchers may be able to find broad-spectrum therapeutic targets for diseases like Zika, dengue, and West Nile.
Scientists at the University of Bath have developed a new technique called Transcription Block Survival (TBS) to accelerate the discovery of cancer-fighting drugs. TBS identifies molecules that can shut down dangerous proteins before they wreak havoc, by blocking their interaction with cell DNA.
Researchers have developed a method to chart the first-ever map of allosteric sites in two common human proteins, revealing they are abundant and identifiable. This could lead to safer, smarter, and more effective medicines by targeting these 'secret doors'.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Vupanorsen, an experimental drug targeting non-HDL cholesterol, showed modest reductions in Non-HDL cholesterol by up to 28%, triglycerides by up to 57%, and angiopoietin-like 3 (ANGPTL3) levels by up to 95% in patients with high cholesterol.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A team of scientists created a powerful new method for generating protein drugs by designing molecules that can target important proteins in the body. The research yielded candidate medicines for cancer, diabetes, infection, inflammation, and beyond, offering a paradigm shift in drug development.
Researchers developed a novel drug to reduce airway mucus that exacerbates common lung diseases. The treatment works by blocking the secretion of mucins, which can block airways and cause life-threatening symptoms.
Researchers have described a pioneering chemical technique that can degrade proteins implicated in cancer, potentially increasing the potency and selectivity of new and existing drugs. This technique, known as proteolysis targeting chimeras (PROTACs), targets specific structures within cancerous cells to reduce harmful side effects.
Researchers at Lewis Katz School of Medicine identify reduced efficiency of protein transport system as key factor in Alzheimer-like changes. The study suggests that targeting the retromer complex could lead to new treatments for Down syndrome-related dementia.
A new discovery could lead to modified thiazolidinediones with fewer side effects, benefiting more patients with diabetes. Activating only PPARγ2 eliminates the risk of weight gain while maintaining anti-diabetic effects.
A team of scientists led by Karine Le Roch has identified two proteins, RAP01 and RAP21, crucial to the malaria parasite's survival. Knocking down these proteins can interrupt protein translation in the mitochondria, leading to the parasite's death.
UC Riverside scientists developed a technique to map tryptophan production, opening the door to new treatment drugs. By understanding how bacteria make tryptophan, researchers can create enzymes that shut down this process, killing invasive bacterial cells without affecting human cells.
Researchers uncover the pleiotropic functions of hnRNPK in regulating skeletal muscle cell differentiation, including inhibition of myoblast differentiation and suppression of genes involved in endoplasmic reticulum stress. The study suggests that targeting hnRNPK could be a potential therapeutic strategy for treating human disorders.
Researchers have identified how IL-36 cytokines instruct proinflammatory CD4+ T cells to accumulate in the inflamed intestine, worsening disease. This discovery offers fresh insights into targeting these proteins as a new therapeutic option for childhood IBD patients.
Scientists at the Princess Máxima Center for Pediatric Oncology discovered a new combination treatment strategy for childhood T-cell acute lymphoblastic leukemia (T-ALL) by analyzing protein activity. The study found that blocking specific proteins, such as LCK and SRC, in combination with an overactive chain reaction of INSR/IGF-1R, k...
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
Researchers discover DUBTACs, which stabilize disease-causing proteins by removing ubiquitin chains, preventing destruction and increasing protein levels. This breakthrough addresses undruggable diseases like cystic fibrosis and cancer, offering a new class of medicines to treat multiple human diseases.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
A UC Riverside-led study has identified a potential antiviral therapy for SARS and SARS-like coronaviruses by targeting the papain-like protease enzyme. The research reveals that subgroup 2b PLpros selectively target specific host immune pathways, making them a promising target for future coronavirus therapeutics.
Scientists have discovered a new subtype of relapsed pediatric AML characterized by a specific gene mutation called UBTF exon 13 tandem duplication (UBTF-TD), which is associated with poor outcomes and an increased incidence of minimal residual disease. This mutation can be used to identify high-risk patients and guide treatment.
Researchers at Johns Hopkins Medicine discovered a peptide on the SARS-CoV-2 spike protein that triggers an immune response in humans and is also recognized by cells of the immune system, suggesting potential for protection against future zoonotic outbreaks. The study supports the development of multivalent vaccines against a broad spe...
Scientists discovered two new targets, EPPIN domains, to block sperm motility, a complex process that allows sperm to reach the egg. The study demonstrates the feasibility of using mice as models for in vivo trials, simplifying preclinical studies and paving the way for novel male contraceptives.
Scientists at Stanford University and SLAC National Accelerator Laboratory have created a molecular cage to study the structure of KIX, a protein used by AML cancer cells. The technique has successfully imaged KIX with cryo-EM, revealing new insights into its function and potential targets for therapy.
Scientists at Scripps Research identified a common target on the spike protein of multiple coronaviruses, including SARS-CoV-2, that can be targeted by a broad-spectrum vaccine. The discovery could inform the design of effective vaccines and antibody therapies against future coronavirus pandemics.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
A University of Houston researcher has identified potential biomarkers for neuropsychiatric symptoms of lupus, which include CSF Lipocalin-2, M-CSF, IgM, and complement C3. Elevated levels of these proteins in cerebrospinal fluid may indicate a diagnosis of NPSLE.
Researchers at UT Health San Antonio have discovered that specific RNA molecules can bind to and inhibit the activity of two proteins (METTL-3 and METTL-14) that drive DNA changes in leukemia. This finding provides a potential therapeutic target for treating this cancer.
A new generation of cholesterol-lowering drugs is being developed to target the PCSK9 protein, which regulates LDL receptor degradation on cells. These therapies have shown promise in reducing LDL levels with fewer side effects than statins.